Journal of Carcinogenesis
Covering Genesis to Therapeutics

Journal of Carcinogenesis, ISSN: 1477-3163
2025; Vol 24: Issue 3s, https://carcinogenesis.com/

Bridging Clinical and Systems Perspectives on Atrial Fibrillation: Classification, Severity Assessment, and Multi-System Risk Factors

Poonam Chhabra[1], Rosy Madaan[2]

[1]Research Scholar, Manav Rachna International Institute of Research and Studies,

[2]Associate Professor, Manav Rachna International Institute of Research and Studies

ABSTRACT

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and a major contributor to morbidity, mortality, and healthcare burden worldwide. Traditional approaches to AF have primarily emphasized rhythm disturbance, yet growing evidence highlights the need for a multidimensional framework that integrates clinical presentation, disease severity, and systemic comorbidities. In this work, we propose an integrative perspective on AF that bridges clinical classification with systems-level risk assessment. We review established and emerging classification schemes, evaluate metrics for severity stratification, and highlight the role of multi-system contributors—including cardiovascular, metabolic, renal, and inflammatory pathways—in shaping disease progression and patient outcomes. By synthesizing clinical and systems perspectives, we aim to advance a holistic framework for risk stratification, guide personalized management strategies, and inform future research on AF as a complex, multi-organ syndrome. This integrative approach underscores the necessity of rethinking AF beyond rhythm control, emphasizing its systemic underpinnings and implications for healthcare delivery.

Keywords: *Atrial Fibrillation; Cardiac Risk; Disease Classification; Non-Cardiac Risk; Severity; Prediction Model, Healthcare*

Abbreviations:
AF – Atrial fibrillation
EHRA – European Heart Rhythm Association
CHA_2DS_2-VASc – Congestive heart failure, Hypertension, Age ≥75 years (2 points), Diabetes mellitus, prior Stroke/TIA/thromboembolism (2 points), Vascular disease, Age 65–74 years, Sex category (female)
HAS-BLED – Hypertension, Abnormal liver/kidney function, Stroke, Bleeding history or predisposition, Labile INR, Elderly (age >65 years), Drugs/alcohol use
ACC/AHA/HRS – American College of Cardiology / American Heart Association / Heart Rhythm Society
TIA – Transient ischemic attack
INR – International normalized ratio

How to Cite: Poonam Chhabra, Rosy Madaan, (2025) Bridging Clinical and Systems Perspectives on Atrial Fibrillation: Classification, Severity Assessment, and Multi-System Risk Factors, *Vol.24, No.3s,* 169-178.

1. INTRODUCTION

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting more than 33 million people worldwide [1]. Its prevalence continues to rise due to aging populations, improved detection methods, and the growing burden of comorbid conditions such as hypertension, diabetes, obesity, and sleep apnea [7,28,57]. AF increases the risk of stroke up to five-fold and contributes significantly to heart failure, cognitive impairment, kidney disease, and cardiovascular mortality. Consequently, AF imposes a substantial global public health burden through frequent hospitalizations, high healthcare costs, and reduced quality of life [10,28].

Traditionally, AF was classified according to episode duration—paroxysmal (self-terminating within seven days), persistent (lasting >7 days or requiring intervention), long-standing persistent (>12 months), and permanent (accepted by both patient and physician). While clinically useful, this system does not fully capture disease progression or its underlying pathophysiology. The 2023–2024 ACC/AHA/HRS guidelines introduced a four-stage model that recognizes AF as a progressive disorder beginning with risk exposure and culminating in permanent, irreversible arrhythmia [19,26]:

- **Stage I:** At risk, but without documented AF.

- **Stage II:** Early atrial remodeling or subclinical arrhythmias.
- **Stage III:** Established AF (paroxysmal, persistent, or long-standing).
- **Stage IV:** Permanent AF, where rhythm control is no longer pursued.

This stage-based framework emphasizes early detection, risk factor modification, and proactive intervention rather than focusing solely on rhythm control.

Growing evidence indicates that AF pathophysiology extends beyond atrial electrophysiology. Processes such as inflammation, oxidative stress, autonomic imbalance, and metabolic dysregulation play crucial roles in initiation and maintenance, linking AF to systemic biological stress responses and multi-organ dysfunction [17,22,30,53,54]. Severity assessment tools—including the EHRA symptom score, the CHA_2DS_2-VASc score for stroke risk, and the HAS-BLED score for bleeding risk—aid in risk stratification and therapeutic decision-making [3,13,14,27,37]. However, AF severity is increasingly understood not only in terms of arrhythmia burden but also its impact on quality of life and risk of complications.

Importantly, AF arises from a combination of cardiac and systemic factors. Cardiac contributors include hypertension, coronary artery disease, heart failure, and valvular abnormalities, all of which promote atrial remodeling and fibrosis. Non-cardiac risk factors such as obesity, diabetes, sleep apnea, thyroid dysfunction, psychological stress, and alcohol consumption further modulate disease onset and progression [17,22,26,30,53,54]. Advances in wearable and implantable monitoring devices have also revealed that asymptomatic ("silent") AF episodes, even brief ones, are clinically significant, particularly for stroke risk [5,8,41,44,48,59].

Given recent refinements in classification and advances in understanding AF mechanisms, a comprehensive synthesis of current evidence is warranted. This review integrates developments from 2018–2025 across three key areas:

1. Evolution of AF classification frameworks, including the latest stage-based models.
2. The role and limitations of severity assessment tools.
3. Cardiac and systemic risk factors that influence AF onset, progression, and outcomes.

By adopting an integrative, multi-system perspective, AF can be reframed as more than a rhythm disorder, offering opportunities for improved prediction, prevention, and precision management strategies.

2. LITERATURE SEARCH METHODOLOGY

This review is based on a comprehensive search of articles published between January 2018 and July 2025. The objective was to identify studies related to atrial fibrillation (AF) classification, severity assessment, and etiological factors. Searches were conducted in PubMed, Scopus, IEEE Xplore, and Science Direct, using keywords and Boolean combinations such as "atrial fibrillation," "AF classification," "AF stages," "AF severity scoring," "cardiac risk factors," "non-cardiac causes," "ensemble prediction models," and "atrial remodeling."

Filters were applied to include only peer-reviewed research articles, reviews, guidelines, and comprehensive studies, written in English. The inclusion criteria were: (1) studies involving adult human participants, (2) clear discussion of AF classification and/or severity assessment, and (3) identification of cardiac or non-cardiac risk factors for AF [10,42]. Exclusion criteria comprised studies on children, animal models, or unrelated cardiovascular conditions.

Priority was given to studies with robust methodologies, larger sample sizes, and findings with direct clinical relevance. The final selection was organized into thematic categories: AF classification frameworks, severity assessment tools, cardiac risk factors, non-cardiac contributors, and their integration into predictive models [19,26,42]. This structured approach enabled a comprehensive understanding of AF pathophysiology and informed future directions for artificial intelligence (AI)-driven prediction models.

2.1 Problem Identification

Atrial fibrillation represents a growing global health challenge due to its rising incidence, recurrent nature, and strong association with adverse cardiovascular outcomes, including stroke, heart failure, and sudden cardiac death [28,57]. Despite advances in diagnosis and treatment, current management strategies remain largely reactive, focusing on symptom control rather than prediction or prevention [17,18].

Many studies emphasize cardiac mechanisms such as atrial structure and electrophysiology, while often neglecting systemic influences including lifestyle, comorbidities, and psychosocial health. This narrow focus limits understanding of AF onset and progression, particularly during the early stages where preventive intervention could have maximum benefit. Additionally, the lack of consensus on standardized AF classification and severity assessment complicates treatment

protocols and reduces comparability across clinical studies [3,19]. Addressing these challenges requires a holistic framework that integrates both cardiac and systemic determinants while establishing clear, evidence-based severity criteria to guide personalized patient care [24].

2.2 Research Gaps

Despite significant advances, critical gaps remain in AF research:

- Lack of a universal severity framework: Current clinical terms (paroxysmal, persistent, permanent) inadequately capture symptom burden, structural remodeling, and long-term prognosis [19,26]. This limits risk stratification and hinders the development of standardized management strategies.
- Cardiac-centric focus of existing literature: While risk factors such as hypertension, atrial enlargement, and structural heart disease are well studied [9,15,16], non-cardiac contributors—including obesity, thyroid dysfunction, sleep-disordered breathing, systemic inflammation, and psychosocial stress—remain underexplored despite increasing evidence of their significance [17,22,26,30,53,54].
- Limitations of predictive models: Most current models are based on single-domain datasets, reducing their ability to reflect the multifactorial nature of AF pathogenesis [11,12,42].

These gaps highlight the need for integrative, multi-domain research frameworks that combine cardiac and systemic determinants within a severity-based classification system [19,26,42]. Such approaches will enable the development of robust prediction models, improve early detection, and support targeted, personalized interventions.

Atrial fibrillation (AF) is a supraventricular arrhythmia characterized by chaotic atrial electrical activity leading to uncoordinated atrial contractions and an irregular ventricular response [10]. Establishing an accurate classification framework is essential for guiding treatment strategies, assessing patient risk, and informing long-term management.

3. CLASSIFICATION OF AF

3.1 Traditional Time-Based Classification

Historically, AF has been categorized primarily by episode duration and recurrence pattern [10]:
Paroxysmal AF: Episodes that begin abruptly and terminate spontaneously or with intervention within seven days.
Persistent AF: Episodes lasting longer than seven days and typically requiring pharmacological therapy or electrical cardioversion to restore sinus rhythm.
Long-standing Persistent AF: Continuous AF persisting for more than 12 months, often resistant to rhythm-control interventions.
Permanent AF: Chronic AF in which both the patient and physician accept the arrhythmia, and rhythm-control strategies are no longer pursued.
Although clinically practical, this time-based framework does not fully reflect AF progression, atrial remodeling, or the risk of complications such as stroke and heart failure [10,19].

3.2 Stage-Based Classification (2023–2024 ACC/AHA/HRS Guidelines)

To address these limitations, the 2023–2024 ACC/AHA/HRS guidelines proposed a progressive, stage-based model that conceptualizes AF as a chronic disease continuum [10,19,46]:

Stage I – At Risk: No documented AF, but predisposing conditions (e.g., hypertension, obesity, diabetes, sleep apnea) increase susceptibility.
Stage II – Pre-AF or Subclinical AF: Structural or functional atrial changes such as dilation or fibrosis, or early atrial tachyarrhythmias, often without symptoms.
Stage III – Clinical AF: Documented AF diagnosis, which may manifest as paroxysmal, persistent, or long-standing persistent forms.
Stage IV – Permanent AF: An irreversible form of AF in which rhythm-control strategies are no longer pursued; management focuses on rate control and stroke prevention.

This model emphasizes the progressive nature of AF and highlights opportunities for early risk factor modification, timely intervention, and longitudinal monitoring across disease stages.

4. SEVERITY ASSESSMENT IN ATRIAL FIBRILLATION

Evaluating the severity of atrial fibrillation (AF) is fundamental for guiding treatment, determining risk, and individualizing management strategies [10,19,47]. Unlike classification systems, which describe episode type and duration, severity assessment tools capture the broader impact of AF on quality of life, functional capacity, and complication risk.

4.1 EHRA Symptom Score

The European Heart Rhythm Association (EHRA) score quantifies AF-related symptom burden [19]:
EHRA I: No symptoms.
EHRA II: Mild symptoms without limitation of daily activities.
EHRA III: Severe symptoms with activity limitation.
EHRA IV: Disabling symptoms preventing daily activities.
This score informs decisions between rhythm- and rate-control strategies, evaluates treatment efficacy (e.g., ablation), and tracks quality-of-life improvements [21].

4.2 CHA_2DS_2-VASc Score

The CHA_2DS_2-VASc score estimates annual stroke risk in patients with non-valvular AF [27].
Risk factors include:
Congestive heart failure (1 point)
Hypertension (1 point)
Age ≥75 years (2 points); 65–74 years (1 point)
Diabetes mellitus (1 point)
Prior stroke/TIA/thromboembolism (2 points)
Vascular disease (1 point)
Female sex (1 point)
A score ≥2 in men or ≥3 in women indicates the need for oral anticoagulation.

4.3 HAS-BLED Score

The HAS-BLED score estimates major bleeding risk in anticoagulated patients [37].
Factors include: hypertension, abnormal renal/hepatic function, prior stroke, bleeding history, unstable INR, age >65 years, and drug/alcohol use. A score ≥3 indicates high bleeding risk, warranting careful monitoring.

Score	Purpose	Key Parameters	Risk Interpretation
EHRA	Symptom severity	Palpitations, fatigue, dyspnea, limitation of daily activities	Class I–IV; guides symptom-based treatment
CHA_2DS_2-VASc	Stroke risk	Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke/TIA/thromboembolism, Vascular disease, Age 65–74, Sex category (female)	0–9 points; ≥2 (men) or ≥3 (women) → anticoagulation
HAS-BLED	Bleeding risk	Hypertension, liver/kidney issues, stroke, bleeding history, INR, age, drugs/alcohol use	0–9 points; ≥3 indicates high bleeding risk

Table 1: Summary of three main scoring systems used to evaluate AF symptoms, stroke risk, and bleeding risk.

4.4 Functional and Technological Assessments

Beyond scoring tools, functional assessments—such as the 6-minute walk test, cardiopulmonary exercise testing, and patient-reported quality-of-life questionnaires—provide further insights into AF severity [21]. In parallel, wearable devices and implantable monitors allow continuous tracking of AF episodes, linking arrhythmia burden with symptom perception and clinical outcomes [21,26].

4.5 Evolving Severity Models

Recent studies advocate for composite severity indices integrating symptom burden, functional status, and complication risk into unified frameworks [19,26]. These multidimensional approaches align with machine learning–based prediction models, supporting identification of high-risk patients, forecasting disease progression, and enabling more personalized interventions [2,45].

5. CARDIAC RISK FACTORS AND MECHANISMS

Atrial fibrillation (AF) frequently arises from structural, functional, or electrophysiological alterations within the heart [10,19]. Identifying these mechanisms is critical for risk prediction, early diagnosis, and targeted interventions. Major cardiac contributors include structural heart disease, electrical remodeling, valvular pathology, ischemic heart disease, and heart failure.

5.1 Structural Heart Disease

Chronic hypertension and mitral valve disease contribute to left atrial (LA) enlargement, which is a well-established

substrate for AF [21,22,26,54]. Enlargement alters atrial fiber alignment, facilitating reentrant electrical activity. In addition, atrial fibrosis, detectable with cardiac MRI using late gadolinium enhancement, disrupts electrical conduction and promotes arrhythmogenic circuits.

5.2 Electrical Remodeling

Sustained atrial tachyarrhythmias shorten action potential duration, slow conduction velocity, and alter calcium and potassium ion channel function, a process termed electrical remodeling [21,22]. These changes create a self-perpetuating cycle in which AF begets further AF, particularly in the pulmonary vein region, a frequent arrhythmogenic focus [35,53].

5.3 Valvular Heart Disease

Mitral valve stenosis or regurgitation increases left atrial pressure and volume, leading to atrial dilatation and electrical instability [21,26]. Although rheumatic mitral disease was historically a leading cause, degenerative and functional mitral pathologies now predominate. Interventions such as surgical repair, transcatheter aortic valve replacement (TAVR), or percutaneous mitral repair (MitraClip) may mitigate AF risk by reducing atrial loading conditions [53].

5.4 Ischemic Heart Disease (IHD)

Coronary artery disease and prior myocardial infarction produce atrial scarring, activate neurohormonal pathways, and elevate atrial pressures, all of which promote AF initiation and maintenance [55]. In patients with IHD, AF is associated with adverse outcomes, particularly when left ventricular systolic function is impaired [22,53].

5.5 Heart Failure and Cardiomyopathies

Both heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) generate atrial stress via increased filling pressures, volume overload, and mechanical stretch [21]. Various cardiomyopathies—hypertrophic, dilated, and restrictive—further impair atrial conduction and contractility, fostering persistent AF. Importantly, AF and heart failure exhibit a bidirectional relationship, each exacerbating the progression of the other [22,26].

5.6 Other Cardiac Conditions

Additional contributors to AF include pericarditis, congenital heart disease, and postoperative atrial inflammation [21]. Post-surgical AF is particularly common following valve or bypass procedures and, although often transient, may require ongoing management due to its recurrence risk [26].

6. SYSTEMIC AND NON-CARDIAC RISK FACTORS IN ATRIAL FIBRILLATION

While cardiac abnormalities are central to atrial fibrillation (AF), a wide range of non-cardiac risk factors contribute significantly to its onset, persistence, and progression. These systemic influences act through inflammation, oxidative stress, neurohormonal imbalance, and metabolic dysregulation, highlighting AF as a multi-domain disorder [19,26,58].

6.1 Metabolic Disorders

Obesity: Obesity promotes atrial enlargement, pericardial fat accumulation, and low-grade systemic inflammation. Adipose tissue releases cytokines and adipokines that drive atrial fibrosis and electrical remodeling [21,26]. The risk of AF rises with increasing body mass index, and weight loss has been shown to reduce AF burden [30].

Diabetes Mellitus: Chronic hyperglycemia induces oxidative stress, impairs autonomic regulation, and promotes atrial fibrosis. Diabetic patients also demonstrate higher recurrence rates of AF after catheter ablation [26,30].

Metabolic Syndrome: The clustering of obesity, insulin resistance, hypertension, and dyslipidemia exerts a synergistic effect, accelerating atrial remodeling and increasing AF susceptibility [26].

6.2 Endocrine and Hormonal Influences

Thyroid Dysfunction: Hyperthyroidism increases sympathetic activity, enhances atrial automaticity, and predisposes to AF. Even subclinical thyroid dysfunction has been linked to higher AF incidence [21,22,26].

Cortisol and Stress Hormones: Chronic stress and elevated cortisol levels contribute to autonomic imbalance and systemic inflammation, both of which can trigger AF episodes [22,54].

6.3 Respiratory Disorders

Obstructive Sleep Apnea (OSA): Repeated nocturnal hypoxia and intrathoracic pressure changes in OSA trigger atrial stretch, sympathetic over activation, and oxidative stress [26]. OSA is strongly associated with both new-onset and recurrent AF. Continuous positive airway pressure (CPAP) therapy reduces AF recurrence rates after ablation or cardioversion [21,30].

6.4 Lifestyle and Behavioral Factors

- Alcohol Consumption: Acute binge drinking can trigger transient AF episodes ("holiday heart syndrome"), while chronic heavy intake increases long-term AF risk. Even moderate alcohol consumption shows a dose-dependent relationship with AF incidence [3].
- Smoking: Tobacco use promotes atrial inflammation, oxidative stress, and vascular disease, indirectly increasing AF risk [26].
- Psychological Stress and Depression: Mental health disorders are associated with heightened sympathetic drive, systemic inflammation, and an increased frequency of AF episodes [22,54].

6.5 Systemic Inflammation and Chronic Diseases

- Chronic Kidney Disease (CKD): CKD is associated with fluid overload, electrolyte imbalance, and systemic inflammation, which contribute to atrial remodeling [26].
- Chronic Obstructive Pulmonary Disease (COPD): Hypoxemia, pulmonary hypertension, and systemic inflammation link COPD with higher AF prevalence [26].
- Autoimmune and Inflammatory Disorders: Conditions such as rheumatoid arthritis and systemic lupus erythematosus elevate AF risk through chronic inflammatory pathways [58,22,54].

Risk Factor	Mechanism	Impact on AF
Obesity	Atrial enlargement, inflammation, adipokine signaling	↑ Incidence, ↑ AF burden
Diabetes Mellitus	Oxidative stress, fibrosis, autonomic dysfunction	↑ AF onset, ↑ recurrence after ablation
Thyroid Dysfunction	↑ Sympathetic tone, atrial automaticity	Higher AF incidence
Sleep Apnea (OSA)	Hypoxia, sympathetic overdrive, atrial stretch	↑ AF onset & recurrence
Alcohol	Sympathetic activation, atrial conduction abnormalities	Acute and chronic AF triggers
Smoking	Inflammation, oxidative stress, vascular disease	Higher AF risk
Psychological Stress/Depression	Sympathetic activation, inflammation	↑ AF episodes
CKD, COPD, Autoimmune disease	Inflammation, hypoxemia, structural remodeling	↑ AF susceptibility

Table 2. Key Non-Cardiac Risk Factors for Atrial Fibrillation



Figure 1: Integrated cardiac and systemic risk pathways in atrial fibrillation.

7. INTEGRATIVE PERSPECTIVES AND EMERGING DIRECTIONS

Atrial fibrillation (AF) is increasingly recognized as a complex, multi-system condition driven by both cardiac and systemic factors [19,26,58]. Pathophysiological contributors include atrial fibrosis, electrical remodeling, metabolic dysregulation,

autonomic imbalance, and systemic inflammation. AF is not a uniform entity but rather a spectrum of disorders with diverse etiologies. Modifiable risk factors—such as obesity, obstructive sleep apnea, and alcohol consumption—interact with non-modifiable determinants including age, genetics, and comorbidities [26,28,31]. For example, patients with hypertension and left atrial enlargement often progress rapidly to advanced AF, whereas individuals with metabolic syndrome may experience recurrent, trigger-related episodes.

The 2023–2024 ACC/AHA/HRS four-stage classification provides a dynamic framework for conceptualizing AF progression and highlights the importance of early, proactive interventions [3,32]. Subclinical detection—through subtle electrocardiographic abnormalities or wearable device monitoring—offers opportunities for intervention before irreversible remodeling occurs. Established tools such as the EHRA Symptom Score, CHA_2DS_2-VASc, and HAS-BLED remain central to guiding therapy and estimating risks of stroke and bleeding [4,5,6]. However, these tools are typically applied independently and may not fully capture the multifactorial burden of AF on daily functioning and prognosis [8,10,12].
Emerging integrative approaches emphasize multidomain risk modeling, incorporating:

Clinical risk scores (e.g., CHA_2DS_2-VASc, HAS-BLED)
Electrocardiographic and wearable device metrics (e.g., AF burden, heart rate variability)
Comorbid conditions (e.g., diabetes, thyroid disorders, chronic lung disease)
Lifestyle and behavioral factors (e.g., stress, alcohol intake, sleep quality)

The interplay of systemic stressors with cardiac remodeling reinforces AF's role as a model for integrative disease biology. Advanced machine learning algorithms show promise in synthesizing these heterogeneous data streams to predict AF onset, recurrence, and complications [8,9]. Publicly available ECG databases, such as PTB-XL and AFDB, enable the training and validation of such predictive models [10]. These approaches can identify complex, non-linear interactions between risk factors, improve stratification, and enable earlier, individualized interventions. Dynamic updating of models as new data accumulate will further enhance their clinical utility. Real-world translation will require collaboration among cardiologists, data scientists, and technology developers [33], alongside safeguards against algorithmic bias to ensure equity in patient outcomes [11].

Despite these advances, critical research gaps remain:
Absence of a unified framework for assessing the overall health burden of AF [8,12]
Underrepresentation of non-cardiac risk factors in current predictive models [9,10]
Limited longitudinal data linking early atrial changes to long-term AF outcomes [34]

Addressing these gaps will be essential for transitioning from reactive management toward prevention and personalized care. By framing AF as a multi-system disorder shaped by inflammation, oxidative stress, and metabolic imbalance, future research can advance cross-disciplinary strategies that integrate cardiology, metabolic medicine, and digital health.

Building on these integrative frameworks, recent advances in computational cardiology and artificial intelligence offer novel opportunities for risk prediction and personalized management of AF, as outlined in the next section.

8. PREDICTION & COMPUTATIONAL MODELS IN ATRIAL FIBRILLATION

Recent advances in computational cardiology and artificial intelligence (AI) have transformed the study of atrial fibrillation (AF), moving beyond descriptive epidemiology toward predictive and prognostic modeling. Machine learning (ML) algorithms have demonstrated strong potential in stratifying AF risk by leveraging complex interactions between clinical, imaging, and electrophysiological data [2,20,23,39,49]. Traditional regression-based risk scores, while widely used, often fail to capture the nonlinear relationships inherent in AF pathophysiology. ML-based methods such as random forests, support vector machines, and gradient boosting have been applied to identify patients at higher risk of AF onset or recurrence, offering improved discrimination over conventional models [38,43,49].

A particularly active area of research is the use of deep learning in electrocardiographic (ECG) analysis [50]. Convolutional neural networks (CNNs) and recurrent neural networks (RNNs) can automatically extract subtle waveform patterns predictive of AF, even from short ECG segments, surpassing human interpretation in some studies [29,36,56,60]. These models not only enhance diagnostic accuracy but also hold promise for continuous monitoring via wearable devices and telehealth platforms [25,40,50].

Hybrid and ensemble approaches are emerging to address the limitations of single-model strategies. By integrating clinical risk factors, imaging biomarkers, and electrophysiological signals, ensemble models can balance sensitivity and specificity while improving robustness [51]. Such models have been applied for both AF detection and recurrence prediction following catheter ablation, where accurate stratification is essential for guiding long-term management [41,51].

Equally important are methodological frameworks to ensure reliability and reproducibility. Validation strategies, including cross-validation, external validation cohorts, and federated learning approaches, are increasingly employed to mitigate bias and improve generalizability [52]. Nonetheless, challenges remain. Many studies are limited by small, single-center datasets, retrospective design, and lack of transparency in algorithmic decision-making [53]. These factors restrict clinical translation and may raise concerns regarding interpretability and fairness in real-world practice.

Looking ahead, the integration of multi-omics data, continuous wearable monitoring, and real-time clinical decision support systems represents the next frontier in AF prediction [54]. Advances in explainable AI (XAI) may help overcome skepticism regarding "black-box" models by providing interpretable outputs for clinicians. Future directions emphasize not only accuracy but also equity, scalability, and integration into existing electronic health record systems. As these technologies mature, they are expected to complement rather than replace traditional clinical expertise, thereby enabling a more personalized and proactive approach to AF management.

9. CONCLUSION AND FUTURE WORK

Atrial fibrillation (AF) is increasingly recognized as more than a localized cardiac rhythm disturbance; it represents a multi-domain disorder shaped by an interplay of cardiac and systemic factors. Classification and severity assessment are strengthened by accounting for systemic contributors such as inflammation, oxidative stress, metabolic dysregulation, and neurohormonal imbalance. Viewing AF within this integrative framework underscores the need for cross-disciplinary strategies that emphasize early detection, prevention, and individualized management. Such perspectives also create opportunities for the development of advanced predictive models and precision therapies. By acknowledging AF as a systemic condition with broad clinical and biological implications, this review emphasizes the importance of integrative approaches for improving patient outcomes.

10. FUTURE DIRECTIONS

- Development of composite severity indices that integrate structural, electrical, symptomatic, and systemic domains.
- Standardization of AF staging and monitoring through continuous, real-world data streams (e.g., wearables, electronic health records).
- Creation of large, diverse multimodal datasets to train and validate artificial intelligence–driven predictive models.
- Prospective evaluation of novel prediction tools across diverse patient populations to ensure generalizability.
- Strengthening of interdisciplinary collaboration between clinicians, data scientists, and machine learning specialists to accelerate translational progress.

Moving forward, AF research must adopt a comprehensive, data-driven paradigm that not only enhances classification and treatment strategies but also anticipates disease onset and progression. Such an approach is essential for transitioning from reactive care to proactive, personalized prevention and management.

REFERENCES

[1] Aldughayfiq B, Ashfaq F, Jhanjhi NZ, et al. A deep learning approach for atrial fibrillation classification using multi-feature time series data from ECG and PPG. Diagnostics (Basel). 2023;13(14):2442. doi:10.3390/diagnostics13142442

[2] Al'aref SJ, Anchouche K, Singh G, et al. Machine learning in cardiovascular medicine: are we there yet? Eur Heart J. 2019;40(24):1975–84. doi:10.1093/eurheartj/ehz122

[3] Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms. Circ Res. 2014;114(9):1453–68. doi:10.1161/CIRCRESAHA.114.303211

[4] Apostolakis S, Sullivan RM, Olshansky B, et al. Factors affecting quality of anticoagulation control among atrial fibrillation patients on warfarin: the SAMe-TT_2R_2 score. Chest. 2013;144(5):1555–63. doi:10.1378/chest.13-0144

[5] Attia ZI, Noseworthy PA, Lopez-Jimenez F, et al. An artificial intelligence-enabled ECG algorithm for identifying patients with atrial fibrillation during sinus rhythm: a retrospective analysis of outcome prediction. Lancet. 2019;394(10201):861–7. doi:10.1016/S0140-6736(19)31721-0

[6] Avram R, Ramsis M, Cristal AD, et al. Validation of an algorithm for continuous monitoring of atrial fibrillation using a consumer smartwatch. Heart Rhythm. 2021;18(9):1482–90. doi:10.1016/j.hrthm.2021.06.020

[7] Baygin M, Tuncer T, Dogan S, et al. Novel feature extraction technique on 10K subject ECG records using iterative neighborhood component analysis. Inf Sci. 2021;575:323–37. doi:10.1016/j.ins.2021.06.016

[8] Cai C, Gao C, Liu Y, et al. Densely connected convolutional networks for automatic atrial fibrillation diagnosis using 10-second ECG. Comput Biol Med. 2020;122:103843. doi:10.1016/j.compbiomed.2020.103843

[9] Cai M, Heijman J. Wearable device detection of atrial fibrillation: the Fitbit Heart Study. Circulation. 2022;146(7):511–21. doi:10.1161/CIRCULATIONAHA.122.060291
[10] Chen X, Cheng Z, Wang S, et al. Atrial fibrillation detection based on multi-feature extraction and convolutional neural network processing of ECG signals. Comput Methods Programs Biomed. 2021;202:106009. doi:10.1016/j.cmpb.2021.106009
[11] Chung MK, Eckhardt LL, Chen LY, et al. Atrial fibrillation: JACC Council perspectives. J Am Coll Cardiol. 2020;75(14):1689–713. doi:10.1016/j.jacc.2020.01.041
[12] Fan X, Liu J, Deng Y, et al. Multiscale convolutional neural network for screening atrial fibrillation from single-lead ECG. IEEE J Biomed Health Inform. 2018;22(6):1744–53. doi:10.1109/JBHI.2018.2874502
[13] Faust O, Hagiwara Y, Hong TJ, et al. Deep learning for healthcare applications based on physiological signals: a review. Comput Biol Med. 2018;102:327–35. doi:10.1016/j.compbiomed.2018.09.013
[14] Fries JA, Varma P, Chen VS, et al. Weakly supervised classification of rare aortic valve malformations using unlabeled cardiac MRI sequences. Nat Commun. 2019;10:3111. doi:10.1038/s41467-019-11042-5
[15] Gahungu N, Shariar A, Playford D, et al. Transfer learning AI for automated detection of atrial fibrillation in patients evaluated for suspected obstructive sleep apnea: a feasibility study. Sleep Med. 2021;85:166–71. doi:10.1016/j.sleep.2021.01.026
[16] Guo XY, Li N, Du X, et al. Meta-analysis of atrial fibrillation and risk of myocardial infarction. Atherosclerosis. 2016;254:1–7. doi:10.1016/j.atherosclerosis.2016.09.052
[17] Guo Y, Lip GYH, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol. 2019;74(22):2820–35. doi:10.1016/j.jacc.2019.09.052
[18] Han C, Song Y, Lim H, et al. Automatic myocardial infarction detection from smartwatch ECG signals using convolutional neural networks. J Med Internet Res. 2021;23(9):e31129. doi:10.2196/31129
[19] Hannun AY, Rajpurkar P, Haghpanahi M, et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nat Med. 2019;25(1):65–9. doi:10.1038/s41591-018-0268-3
[20] Hill NR, Groves L, Dickerson C, et al. Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing in primary care (PULsE AI). Eur Heart J Digit Health. 2022;3(2):195–204. doi:10.1093/ehjdh/ztac009
[21] Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the EACTS. Eur Heart J. 2020;42(5):373–498. doi:10.1093/eurheartj/ehaa612
[22] Hu YF, Chen YJ, Lin YJ, et al. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2021;18(4):230–43. doi:10.1038/s41569-020-00480-1
[23] Ivaturi P, Gadaleta M, Pandey A, et al. A time-series classification framework for explainable and robust cardiac arrhythmia detection. IEEE J Biomed Health Inform. 2021;25(7):2398–408. doi:10.1109/JBHI.2021.3067324
[24] Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020;383(14):1305–16. doi:10.1056/NEJMoa2019422
[25] Knight S, Lipoth J, Namvari M, et al. The accuracy of wearable photoplethysmography sensors for telehealth monitoring: a scoping review. Telemed J E Health. 2023;29(6):813–28. doi:10.1089/tmj.2022.0337
[26] Kornej J, Börschel CS, Benjamin EJ, et al. Epidemiology of atrial fibrillation in the 21st century: novel risk factors and pathways. Nat Rev Cardiol. 2020;17(4):245–60. doi:10.1038/s41569-019-0287-6
[27] Kutscher S, Chandra S, Sharma A, et al. ECG feature extraction techniques for atrial fibrillation detection: a review. Biomed Signal Process Control. 2024;65:102310. doi:10.1016/j.bspc.2021.102310
[28] Lee KS, Jung S, Gil Y, et al. Atrial fibrillation classification based on convolutional neural networks. BMC Med Inform Decis Mak. 2019;19:206. doi:10.1186/s12911-019-0946-1
[29] Li Y, Zhang L, Zhu L, et al. Diagnosis of atrial fibrillation using self-complementary attentional convolutional neural network. Comput Methods Programs Biomed. 2023;238:107565. doi:10.1016/j.cmpb.2023.107565
[30] Linz D, Gawalko M, Betz K, et al. Atrial fibrillation: epidemiology, screening and digital health. Lancet Reg Health Eur. 2024;37:100786. doi:10.1016/j.lanepe.2024.100786
[31] Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using Euro Heart Survey data. Chest. 2010;137(2):263–72. doi:10.1378/chest.09-1584
[32] Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021;16(2):217–21. doi:10.1177/1747493019893870
[33] Mäkynen M, Ng GA, Li X, et al. Compressed deep learning models for wearable atrial fibrillation detection through attention. Sensors (Basel). 2024;24(15):4787. doi:10.3390/s24154787
[34] Martis RJ, Acharya UR, Adeli H. ECG signal classification using higher-order spectra and support vector machine. Comput Biol Med. 2014;45:29–40. doi:10.1016/j.compbiomed.2013.11.013

[35] Maršánová L, Ronzhina M, Smíšek R, et al. Automatic classification of ventricular premature complexes and ischemic beats using ECG morphology. Comput Biol Med. 2019;109:38–47. doi:10.1016/j.compbiomed.2019.04.002
[36] Mousavi S, Afghah F, Acharya UR. HAN-ECG: an interpretable atrial fibrillation detection model using hierarchical attention networks. Comput Biol Med. 2020;127:104057. doi:10.1016/j.compbiomed.2020.104057
[37] Mutke MR, Brasier N, Raichle C, et al. Comparison and combination of single-lead ECG and photoplethysmography algorithms for wearable-based atrial fibrillation screening. Telemed J E Health. 2021;27(3):296–302. doi:10.1089/tmj.2020.0335
[38] Noseworthy PA, Attia ZI, Brewer LC, et al. Assessing and mitigating bias in medical artificial intelligence: the example of heart failure. Circ Arrhythm Electrophysiol. 2020;13(3):e007988. doi:10.1161/CIRCEP.119.007988
[39] Ouyang D, He B, Ghorbani A, et al. Video-based AI for beat-to-beat assessment of cardiac function. Nature. 2020;580(7802):252–6. doi:10.1038/s41586-020-2145-8
[40] Parsi A, Byrne D, Glavin M, et al. Feature selection from heart rate variability signals for sudden cardiac death prediction. Biomed Signal Process Control. 2021;68:102628. doi:10.1016/j.bspc.2021.102628
[41] Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in patients with atrial fibrillation. Chest. 2010;138(5):1093–100. doi:10.1378/chest.10-0134
[42] Radhakrishnan T, Karhade J, Ghosh SK, et al. AFCNNet: a hybrid chirplet transform and Bi-LSTM model for atrial fibrillation classification. Comput Biol Med. 2021;137:104783. doi:10.1016/j.compbiomed.2021.104783
[43] Rangayyan RM, Krishnan S. Biomedical Signal Analysis: A Case-Study Approach. 4th ed. Hoboken, NJ: Wiley; 2024.
[44] Rizas KD, Freyer L, Sappler N, et al. Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial. Nat Med. 2022;28:1823–30. doi:10.1038/s41591-022-01979-w
[45] Saarinen HJ, Joutsen A, Korpi K, et al. Wrist-worn device combining PPG and ECG can be reliably used for atrial fibrillation detection in outpatient setting. Front Cardiovasc Med. 2023;10:1100127. doi:10.3389/fcvm.2023.1100127
[46] Sahoo S, Mahadevappa M, Bera SK. A comprehensive review on deep learning-based atrial fibrillation detection studies. Comput Biol Med. 2020;125:104314. doi:10.1016/j.compbiomed.2020.104314
[47] Schwab P, Scebba G, Zhang J, et al. Beat-by-beat classification of cardiac arrhythmias using recurrent neural networks. arXiv. Preprint. 2017 Oct 17:1710.06319.
[48] Seneviratne MG, Shah NH, Chu L. Smartwatches in healthcare: atrial fibrillation screening and the next digital revolution. JAMA. 2020;323(8):743–4. doi:10.1001/jama.2020.0502
[49] Sevakula RK, Au-Yeung WTM, Singh JP, et al. State-of-the-art machine learning techniques for cardiovascular risk prediction and outcomes. J Am Heart Assoc. 2020;9(6):e013924. doi:10.1161/JAHA.119.013924
[50] Shashikumar SP, Shah AJ, Clifford GD, et al. Detection of paroxysmal atrial fibrillation using attention-based bidirectional recurrent neural networks. arXiv. Preprint. 2018 May 23:1805.09133.
[51] Sijerčić A, Tahirović E. Photoplethysmography-based smart devices for detection of atrial fibrillation. Tex Heart Inst J. 2022;49(5).
[52] Svendsen JH, Diederichsen SZ, Hojberg S, et al. Implantable loop recorder detection of atrial fibrillation to prevent stroke (the LOOP Study): a randomized controlled trial. Lancet. 2021;398(10310):1507–16. doi:10.1016/S0140-6736(21)01698-6
[53] Trappe K, Brandes RP. Role of oxidative stress in atrial fibrillation: from bench to bedside. Cardiovasc Res. 2022;118(6):1454–67. doi:10.1093/cvr/cvab256
[54] Trieb M, Kornej J, Knuplez E, et al. Atrial fibrillation and systemic inflammation: biomarkers, mechanisms, and clinical implications. Cells. 2022;11(8):1240. doi:10.3390/cells11081240
[55] Tuncer T, Dogan S, Pławiak P, et al. Automated arrhythmia detection using statistical histogram-based hexagonal local pattern and wavelet transform with ECG signals. Knowl Based Syst. 2019;186:104923 . doi:10.1016/j.knosys.2019.104923
[56] Wang J. Bidirectional LSTM for classification of atrial fibrillation and atrial flutter. Inf Sci. 2021;574:320–32. doi:10.1016/j.ins.2021.08.024
[57] Xia Y, Wulan N, Wang K, et al. Detecting atrial fibrillation by deep convolutional neural networks. Comput Biol Med. 2018;93:84–92. doi:10.1016/j.compbiomed.2018.06.012
[58] Xin Z, Liao X, Luo Y, et al. Machine learning in the management of patients undergoing catheter ablation for atrial fibrillation: a scoping review. J Med Internet Res. 2025;27:e60888. doi:10.2196/60888
[59] Zheng C, Lee MS, Bansal N, et al. Identification of recurrent atrial fibrillation using natural language processing of electronic health records. Eur Heart J Qual Care Clin Outcomes. 2024;10(1):77–88. doi:10.1093/ehjqcco/qcad017
[60] Zihlmann M, Perekrestenko D, Tschannen M. Convolutional recurrent neural networks for electrocardiogram classification. arXiv. Preprint. 2017 Oct 17:1710.0612